🇺🇸 FDA
Patent

US 10745475

Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics

granted A61KA61K2039/54A61K39/3955

Quick answer

US patent 10745475 (Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics) held by TAKEDA GMBH expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TAKEDA GMBH
Grant date
Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/54, A61K39/3955, A61P, A61P17/06